全球滅菌管焊機市場：COVID-19 的增長、趨勢、影響、預測（2022-2027 年）

在預測期內，無菌管焊機的全球市場規模預計將以 4% 的複合年增長率增長。

這是由於研發成本增加以及對醫院和研究診所整體需求的增加。

一次性技術的引入以及對血液和血液製品不斷增長的需求也在支持市場的增長。此外，無菌管焊機的市場正在擴大，因為無菌轉移是一個重要的過程，在血液治療和生物製藥等各個領域發揮著重要作用。此外，大量輸血增加了血液製品的需求和採用，推動了整個市場的增長。

本報告調查了全球無菌管焊機市場，提供了市場概況、按模式、應用、最終用戶和地區劃分的趨勢，以及進入市場的公司概況。我是。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第四章市場動態

• 市場概況
• 市場促進因素
  • 研發費用增加
  • 醫院和研究診所的需求不斷增加
• 市場製約因素
  • 存在替代品
• 波特五力分析

第 5 章市場細分

• 按模式
  • 自動
  • 手冊
• 按應用
  • 血液治療
  • 生物製藥
  • 診斷實驗室
  • 其他
• 最終用戶
  • 醫院
  • 研究診所
  • 其他
• 按地區
  • 北美
  • 歐洲
  • 亞太地區
  • 中東/非洲
  • 南美洲

第6章競爭態勢

• 公司簡介
  • Cytiva (GE Healthcare)
  • TERUMO BCT, INC.
  • Genesis BPS
  • MGA Technologies
  • SARTORIUS AG
  • Entegris, Inc.
  • BIOMEN BIOSYSTEMS COMPANY LIMITED
  • Vante Biopharm/Sebra

第7章 市場機會與未來動向

The Sterile Tubing Welder Market is expected to register a CAGR of 4% during the forecast period. This is attributing to increasing R&D expenditure, growing demand across hospitals and research clinics. In addition, the rising adoption of Single-use technologies and increasing demand for blood and blood products are also fueling the revenue growth of the market. As these sterile tubings are welders are important processes in because sterile transfers play a major role in various areas such as blood processing, biopharmaceuticals etc. thus results in propelling the market. According to a report published by the National Institute of Health (NIH), an estimate of 85 million units is transfused (blood transfusion) globally. These are transfused for the treatment of hematologic disorders such as anemia, leukemia, sickle cell diseases. With such a huge number of transfusions taking place results in high demand and adoption of blood products thus promoting the growth of the overall market. Moreover, contamination of blood results in wastage, improper storage, lack of proper handling associated with blood processing is some more factors that are boosting the demand of automated sterile tubing welder and further drive the market.

Key Market Trends

Sterile Tubing Welder in Blood Processing is Estimated to Witness a Healthy Growth in Future.

Sterile tubing welder in blood processing is estimated to witness a healthy growth in the future attributing to the high demand for personalized medicines, increasing prevalence of blood disorders, rising demand for blood and blood products and increasing cell and gene therapy. As per the World Federation of Hemophilia, in 2018 around 210,454 people had experienced hemophilia results in boosting the demand for Sterile tubing welder Market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Sterile Tubing Welder Market due to the increasing demand for a hygienic and sterile environment, rising prevalence of chronic diseases, technological advancements, healthcare expenditure and presence of well-established healthcare infrastructure. As per the American Red Cross, an estimate of 36000 units of red blood cells is needed every day and around 21 million blood components are transfused each year in the United States. Thus surge the demand for blood transfusion in the United States and promotes the growth of the sterile tubing market in this region.

Competitive Landscape

The Sterile Tubing Welder Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Cytiva (GE Healthcare), TERUMO BCT, INC., Genesis BPS, MGA Technologies, SARTORIUS AG, Entegris, Inc., BIOMEN BIOSYSTEMS COMPANY LIMITED, and Vante Biopharm / Sebra.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing R&D Expenditure
  • 4.2.2 Growing Demand across Hospitals and Research Clinics
• 4.3 Market Restraints
  • 4.3.1 Presence of Alternatives
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Mode
  • 5.1.1 Automatic
  • 5.1.2 Manual
• 5.2 By Applications
  • 5.2.1 Blood Processing
  • 5.2.2 Biopharmaceuticals
  • 5.2.3 Diagnostic Laboratories
  • 5.2.4 Others
• 5.3 By End Users
  • 5.3.1 Hospitals
  • 5.3.2 Research Clinics
  • 5.3.3 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Cytiva (GE Healthcare)
  • 6.1.2 TERUMO BCT, INC.
  • 6.1.3 Genesis BPS
  • 6.1.4 MGA Technologies
  • 6.1.5 SARTORIUS AG
  • 6.1.6 Entegris, Inc.
  • 6.1.7 BIOMEN BIOSYSTEMS COMPANY LIMITED
  • 6.1.8 Vante Biopharm / Sebra

7 MARKET OPPORTUNITIES AND FUTURE TRENDS